1.Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.
Qingxin LIU ; Danielle JERNIGAN ; Yun ZHANG ; Alessandro FATATIS
Chinese Journal of Cancer 2011;30(9):612-619
Metastasis represents by far the most feared complication of prostate carcinoma and is the main cause of death for patients. The skeleton is frequently targeted by disseminated cancer cells and represents the sole site of spread in more than 80% of prostate cancer cases. Compatibility between select malignant phenotypes and the microenvironment of colonized tissues is broadly recognized as the culprit for the organ-tropism of cancer cells. Here, we review our recent studies showing that the expression of platelet-derived growth factor receptor alpha (PDGFRα) supports the survival and growth of prostate cancer cells in the skeleton and that the soluble fraction of bone marrow activates PDGFRα in a ligand-independent fashion. Finally, we offer pre-clinical evidence that this receptor is a viable target for therapy.
Animals
;
Antibodies, Monoclonal
;
therapeutic use
;
Bone Marrow
;
enzymology
;
pathology
;
Bone Neoplasms
;
prevention & control
;
secondary
;
Enzyme Activation
;
Humans
;
Male
;
Prostatic Neoplasms
;
drug therapy
;
enzymology
;
pathology
;
Receptor, Platelet-Derived Growth Factor alpha
;
antagonists & inhibitors
;
genetics
;
immunology
;
metabolism
;
Signal Transduction
;
Transcriptional Activation
2.Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis.
Sang Hyuk PARK ; Sollip KIM ; Chan Jeoung PARK ; Seongsoo JANG ; Hyun Sook CHI ; Kyung Nam KOH ; Ho Joon IM ; Jong Jin SEO
Annals of Laboratory Medicine 2013;33(2):89-96
BACKGROUND: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy. METHODS: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy. RESULTS: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P=0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P=0.852). CONCLUSIONS: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Bone Marrow/*pathology
;
Bone Marrow Cells/*cytology
;
Bone Marrow Neoplasms/*diagnosis/secondary
;
Cell Differentiation
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Infant
;
Karyotyping
;
Male
;
Neoplasm Grading
;
Neuroblastoma/*diagnosis/drug therapy/pathology
;
Prognosis
;
Survival Analysis
;
Young Adult
3.Primary non-Hodgkin's Lymphoma of the Bladder with Bone Marrow Involvement.
The Korean Journal of Internal Medicine 2003;18(1):40-44
Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare. A 35-year-old man was admitted to our hospital with a chief complaint of gross hematuria with left flank pain on April 12, 2001. Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type. Abdomino-pelvic CT scan demonstrated left-side hydronephrosis and hydroureter with left proximal ureter infiltration and thickening of the left lateral wall of the bladder with perivesical fat infiltration without lymph node enlargement. Full-scale staging work-up revealed the bone marrow as the solely involved site. The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and predinisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
Adult
;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
;
Biopsy, Needle
;
Bone Marrow/*pathology
;
Bone Neoplasms/pathology/*secondary
;
Cyclophosphamide/*administration & dosage
;
Cystoscopy
;
Doxorubicin/*administration & dosage
;
Follow-Up Studies
;
Humans
;
Immunohistochemistry
;
Lymphoma, Non-Hodgkin/drug therapy/*pathology
;
Male
;
Neoplasm Staging
;
Prednisone/*administration & dosage
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Urinary Bladder Neoplasms/drug therapy/*pathology
;
Urodynamics
;
Vincristine/*administration & dosage
4.Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma.
Young Bae CHOI ; Go Eun BAE ; Na Hee LEE ; Jung Sun KIM ; Soo Hyun LEE ; Keon Hee YOO ; Ki Woong SUNG ; Hong Hoe KOO
Journal of Korean Medical Science 2015;30(8):1062-1067
The records of 63 high-risk neuroblastoma patients with bone marrow (BM) tumors at diagnosis were retrospectively reviewed. All patients received nine cycles of induction chemotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT). Follow-up BM examination was performed every three cycles during induction chemotherapy and every three months for one year after the second HDCT/auto-SCT. BM tumor cells persisted in 48.4%, 37.7%, 23.3%, and 20.4% of patients after three, six, and nine cycles of induction chemotherapy and three months after the second HDCT/auto-SCT, respectively. There was no difference in progression-free survival (PFS) rate between patients with persistent BM tumor and those without during the induction treatment. However, after tandem HDCT/auto-SCT, the PFS rate was worse in patients with persistent BM tumor than in those without (probability of 5-yr PFS 14.7% +/- 13.4% vs. 64.2% +/- 8.3%, P = 0.009). Persistent BM tumor during induction treatment is not associated with a worse prognosis when intensive tandem HDCT/auto-SCT is given as consolidation treatment. However, persistent BM tumor after tandem HDCT/auto-SCT is associated with a worse prognosis. Therefore, further treatment might be needed in patients with persistent BM tumor after tandem HDCT/auto-SCT.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
;
Bone Marrow Neoplasms/pathology/*secondary/*therapy
;
Child
;
Child, Preschool
;
Combined Modality Therapy/methods
;
Female
;
Humans
;
Induction Chemotherapy/methods
;
Infant
;
Infant, Newborn
;
Male
;
Neoplasms, Multiple Primary/pathology/*therapy
;
Neuroblastoma/*pathology/*therapy
;
Prognosis
;
Retrospective Studies
;
Risk Factors
;
Stem Cell Transplantation/*methods
;
Treatment Outcome
;
Young Adult